Brind.

Daiichi Sankyo and AstraZeneca are nearing a UK pricing deal for Enhertu, while Morgan Stanley and Bank of America issued recent rating updates.

1 report, 1 independent Updated Jul 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Daiichi Sankyo AstraZeneca

Keep exploring

The entities involved

Daiichi Sankyo
Japanese pharmaceutical company
- A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.Sun 09:52
- The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Sun 09:52
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52

Coverage

Newest first; wire copies grouped

Jul 9tickerreport.com